Literature DB >> 14656029

Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk.

Wolfgang Herrmann1, Rima Obeid, Heike Schorr, Jürgen Geisel.   

Abstract

BACKGROUND: The prevalence of a sub-clinical functional vitamin B12 deficiency in the general population is higher than previously expected. Total serum vitamin B12 may not reliably indicate vitamin B12 status. To get more specificity and sensitivity in diagnosing vitamin B12 deficiency, the concept of measuring holotranscobalamin II (holoTC), a sub-fraction of vitamin B12, has aroused great interest. HoloTC as a biologically active vitamin B12 fraction promotes a specific uptake of its vitamin B12 by all cells. In this study we investigated the diagnostic value of storage (holoTC) of vitamin B12 and functional markers (methylmalonic acid (MMA)) of vitamin B12 metabolism in populations who are at risk of vitamin B12 deficiency. SUBJECTS AND METHODS: Our study included 93 omnivorous German controls, 111 German and Dutch vegetarian subjects, 122 Syrian apparently healthy subjects, 127 elderly Germans and finally 92 German pre-dialysis renal patients. Serum concentrations of homocysteine (Hcy) and MMA were measured by gas chromatography-mass spectrometry, folate and vitamin B12 by chemiluminescence immunoassay, and holoTC by utilizing a RIA test.
RESULTS: High Hcy (>12 micromol/l), high MMA (>271 nmol/l) resp. low holoTC (vitamin B12) in serum were detected in 15%, 8% resp. 13% (1%) of German controls, 36%, 60%, resp. 72% (30%) of vegetarians, 42%, 48% resp. 50% (6%) of Syrians, 75%, 42%, resp. 21% (7%) of elderly subjects and 75%, 67% resp. 4% (2%) of renal patients. The lowest median levels of holoTC were observed in vegetarians, followed by the Syrian subjects (23 and 35 pmol/l, respectively). Renal patients had significantly higher levels of holoTC compared to the German controls (74 vs. 54 pmol/l). In the vitamin B12 range between 156 pmol/l (conventional cut-off level) and 241 pmol/l, both mean concentrations of holoTC and MMA were in the pathological range. HoloTC was the earliest marker for vitamin B12 deficiency followed by MMA. Vitamin B12 deficiency causes folate trapping. A higher folate level is required to keep Hcy normal. The relationship between MMA and holoTC seemed dependent on renal function. In renal patients with a glomerular filtration rate below 36 ml/min, a significantly lower mean level of MMA was detected within the highest tertile of holoTC concentration, compared to the lowest tertile. Thus, in renal patients, a higher serum concentration of circulating holoTC is required to deliver sufficient amounts of holoTC into the cells.
CONCLUSION: Our data support the concept that the measurement of holoTC and MMA provides a better index of cobalamin status than the measurement of total vitamin B12. HoloTC is the most sensitive marker, followed by MMA. The use of holoTC and MMA enables us to differentiate between storage depletion and functional vitamin B12 deficiency. Renal patients have a higher requirement of circulating holoTC. In renal dysfunction, holoTC cannot be used as a marker of vitamin B12 status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656029     DOI: 10.1515/CCLM.2003.227

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  38 in total

1.  Highlights From the Institute for Functional Medicine's 2014 Annual Conference: Functional Perspectives on Food and Nutrition: The Ultimate Upstream Medicine.

Authors:  Lara Pizzorno
Journal:  Integr Med (Encinitas)       Date:  2014-10

Review 2.  [Folic acid and vitamin B12 determination in the assessment of cognitive disorders : Overview and data analysis from a university outpatient memory clinic].

Authors:  Robert Haußmann; Cathrin Sauer; Stefanie Neumann; Anne Zweiniger; Jan Lange; Markus Donix
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

Review 3.  Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review.

Authors:  Lindsay H Allen; Joshua W Miller; Lisette de Groot; Irwin H Rosenberg; A David Smith; Helga Refsum; Daniel J Raiten
Journal:  J Nutr       Date:  2018-12-01       Impact factor: 4.798

4.  Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes.

Authors:  Wiebke Schrempf; Marco Eulitz; Volker Neumeister; Gabriele Siegert; Rainer Koch; Heinz Reichmann; Alexander Storch
Journal:  J Neurol       Date:  2010-10-02       Impact factor: 4.849

Review 5.  Diagnosing vitamin B-12 deficiency on the basis of serum B-12 assay.

Authors:  Vinod Devalia
Journal:  BMJ       Date:  2006-08-19

6.  Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification.

Authors:  Martha Savaria Morris; Paul F Jacques; Irwin H Rosenberg; Jacob Selhub
Journal:  Am J Clin Nutr       Date:  2007-01       Impact factor: 7.045

7.  Low holotranscobalamin and cobalamins predict incident fractures in elderly men: the MrOS Sweden.

Authors:  C Lewerin; H Nilsson-Ehle; S Jacobsson; H Johansson; V Sundh; M K Karlsson; Ö Ljunggren; M Lorentzon; J A Kanis; U H Lerner; S R Cummings; C Ohlsson; D Mellström
Journal:  Osteoporos Int       Date:  2013-10-16       Impact factor: 4.507

Review 8.  Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies.

Authors:  Ralph Green
Journal:  Am J Clin Nutr       Date:  2011-07-06       Impact factor: 7.045

9.  Fraction of total plasma vitamin B12 bound to transcobalamin correlates with cognitive function in elderly Latinos with depressive symptoms.

Authors:  Marjorie G Garrod; Ralph Green; Lindsay H Allen; Dan M Mungas; William J Jagust; Mary N Haan; Joshua W Miller
Journal:  Clin Chem       Date:  2008-05-01       Impact factor: 8.327

10.  Transcobalamin-II variants, decreased vitamin B12 availability and increased risk of frailty.

Authors:  A M Matteini; J D Walston; K Bandeen-Roche; D E Arking; R H Allen; L P Fried; A Chakravarti; S P Stabler; M D Fallin
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.